Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient

In France, lung cancer is the leading cause of death induced by cancer. Therapeutic advances have been made in therapy of unresectable non-small cell lung cancer (NSCLC) with tyrosine kinase receptor ...

Lead sponsor: University Hospital, Angers•8 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Trial snapshot

StatusUNKNOWN

PhasePHASE2

Enrollment80

Start dateFeb 2014

Last updatedFeb 24, 2014

Condition

No EGFR Activating Mutation

Locations shown

University Hospital, Bordeaux

Bordeaux, Gironde

Army Hospital, Percy

Percy, Haut de Seine

University Hospital, Toulouse

Toulouse, Haute Garonne

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 24, 2014Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions